Concepedia

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial

Angela Applebee, Andrew Goodman, Angeli Mayadev, François Béthoux, Myla Goldman, Michael Klingler, Andrew R. Blight, Enrique Carrazana

Clinical Therapeutics · 2015 · 20 citations · 9 references

DOIFull text

Open access

Concepts

References

9

Measuring the impact of MS on walking ability

Jeremy Hobart, Afsane Riazi, Donna L. Lamping et al. · Neurology · 2003 · 806 citations

, , +16

Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls

Myla Goldman, Ruth Ann Marrie, Jeffrey A. Cohen · Multiple Sclerosis Journal · 2007 · 674 citations

, , +16

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

Andrew Goodman, Theodore R. Brown, Lauren Krupp et al. · The Lancet · 2009 · 549 citations

, , +8

Impact of Walking Impairment in Multiple Sclerosis

Nicholas G. LaRocca · Patient · 2011 · 503 citations

, , +12

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

Andrew Goodman, Theodore R. Brown, Keith R. Edwards et al. · Annals of Neurology · 2010 · 373 citations

, , +12